Skip to main content
Clinical Trials/NCT03385330
NCT03385330
Completed
Not Applicable

The Bronchopulmonary Dysplasia Saturation TARgeting (BPD STAR) Pilot Trial

Children's Hospital of Philadelphia3 sites in 1 country50 target enrollmentJune 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchopulmonary Dysplasia
Sponsor
Children's Hospital of Philadelphia
Enrollment
50
Locations
3
Primary Endpoint
Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Bronchopulmonary dysplasia (BPD), or chronic lung disease of prematurity, affects nearly half of extremely preterm infants.This study evaluates the use of supplemental oxygen to manage infants with established BPD. Participants will be randomly placed in either a higher oxygen saturation group or a lower oxygen saturation target group.

Detailed Description

Bronchopulmonary Dysplasia is diagnosed only in babies who are born prematurely, and affects about half of extremely preterm infants. The incidence of BPD has increased over time. It is most commonly defined as oxygen dependence at 36 weeks postmenstrual age (PMA). Infants with BPD face more than doubled odds of death after 36 weeks PMA or disability at 5 years compared to preterm infants without BPD. BPD is associated with abnormal lung function throughout childhood and significantly increases health care costs. Cognitive and respiratory outcomes are closely linked throughout the life course; thus, optimal long--term management of BPD during infancy may ultimately improve cognitive outcomes of this high--risk population. Supplemental oxygen is a lifesaving therapy for premature infants; yet, there is limited evidence about the safety or efficacy of using supplemental oxygen to target higher versus lower oxygen saturations in infants with established BPD. Infants between the ages of 34-44 weeks post-menstrual age with moderate or severe BPD will be randomly assigned to higher or lower oxygen saturation target ranges. The study intervention will begin in the hospital and will continue at home until 6 months corrected age. When infants are discharged with supplemental oxygen, this will be titrated according to a study algorithm in order to ensure that the target saturations are maintained throughout the study period.

Registry
clinicaltrials.gov
Start Date
June 1, 2018
End Date
September 1, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sara B. DeMauro, MD MSCE

Assistant Professor of Pediatrics

Children's Hospital of Philadelphia

Eligibility Criteria

Inclusion Criteria

  • Pre-term males or females infants born at \<30 0/7 weeks gestation at birth
  • Current age 34 0/7 to 43 6/7 weeks postmenstrual age
  • Diagnosis of moderate or severe Bronchopulmonary Dysplasia based on the NIH consensus definition
  • Infant has never been discharged to home from the hospital

Exclusion Criteria

  • Congenital anomaly or oncologic process likely to affect growth or respiratory status
  • Hemoglobinopathy or other blood disorder likely to affect oxygen saturations
  • Contraindication to nasal cannula use (for example, severe nasal septal breakdown).
  • Pulmonary hypertension requiring pharmacotherapy at the time of screening/enrollment.
  • Tracheostomy
  • Intubated during entire eligibility period

Outcomes

Primary Outcomes

Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time

Time Frame: Between discharge and 6 months corrected age

Incidence of intermittent hypoxia (IH, defined as SpO2 \<80% for \>=30 seconds), reported as median number of events per 8 hours of monitoring time.

Secondary Outcomes

  • Change in Weight Z-score(Between randomization and 6 months corrected age)
  • Number of Participants With Respiratory Medication Use(At 6 months corrected age)
  • Duration of Hypoxia - Proportion of Monitored Time With Oxygen Saturation <80%(Between discharge and 6 months corrected age)
  • Number of Participants With Re-hospitalization(Between discharge and 6 months corrected age)
  • Change in Length Z-score(Between randomization and 6 months corrected age)
  • Change in Head Circumference Z-score(Between randomization and 6 months corrected age)
  • Number of Participants With Visits to Emergency Room or Urgent Care for Respiratory Reasons(Between discharge and 6 months corrected age)
  • Feeding(At 6 months corrected age)
  • Development(At 6 months corrected age)

Study Sites (3)

Loading locations...

Similar Trials